Free Trial

IDEAYA Biosciences (IDYA) Stock Forecast & Price Target

IDEAYA Biosciences logo
$26.54 -0.25 (-0.93%)
(As of 11:23 PM ET)

IDEAYA Biosciences - Analysts' Recommendations and Stock Price Forecast (2024)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Sell
0
Hold
2
Buy
14

Based on 16 Wall Street analysts who have issued ratings for IDEAYA Biosciences in the last 12 months, the stock has a consensus rating of "Moderate Buy." Out of the 16 analysts, 2 have given a hold rating, 13 have given a buy rating, and 1 has given a strong buy rating for IDYA.

Consensus Price Target

$53.67
102.21% Upside
According to the 16 analysts' twelve-month price targets for IDEAYA Biosciences, the average price target is $53.67. The highest price target for IDYA is $68.00, while the lowest price target for IDYA is $27.00. The average price target represents a forecasted upside of 102.21% from the current price of $26.54.
Get the Latest News and Ratings for IDYA and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for IDEAYA Biosciences and its competitors.

Sign Up

IDYA Analyst Ratings Over Time

TypeCurrent Forecast
11/26/23 to 11/25/24
1 Month Ago
10/27/23 to 10/26/24
3 Months Ago
8/28/23 to 8/27/24
1 Year Ago
11/26/22 to 11/26/23
Strong Buy
1 Strong Buy rating(s)
1 Strong Buy rating(s)
1 Strong Buy rating(s)
0 Strong Buy rating(s)
Buy
13 Buy rating(s)
14 Buy rating(s)
12 Buy rating(s)
12 Buy rating(s)
Hold
2 Hold rating(s)
0 Hold rating(s)
0 Hold rating(s)
0 Hold rating(s)
Sell
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
Consensus Price Target$53.67$55.45$55.70$33.42
Forecasted Upside102.21% Upside89.26% Upside41.55% Upside4.43% Upside
Consensus Rating
Moderate Buy
Buy
Buy
Buy

IDYA Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

IDYA Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

IDEAYA Biosciences Stock vs. The Competition

TypeIDEAYA BiosciencesMedical CompaniesS&P 500
Consensus Rating Score
2.94
2.80
2.50
Consensus RatingModerate BuyModerate BuyModerate Buy
Predicted Upside99.21% Upside26,609.51% Upside6.16% Upside
News Sentiment Rating
Neutral News

See Recent IDYA News
Positive News
Positive News
DateBrokerageAnalyst NameActionRatingPrice TargetUpside/Downside on Report DateDetails
11/18/2024Stephens
4 of 5 stars
S. Loganathan
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageOverweight$51.00+91.44%
11/5/2024Leerink Partnrs
5 of 5 stars
A. Berens
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeStrong-Buy ➝ Hold
11/5/2024Leerink Partners
1 of 5 stars
 DowngradeOutperform ➝ Market Perform$41.00 ➝ $27.00-10.00%
11/4/2024Wedbush
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingOutperform$52.00+73.33%
10/29/2024Oppenheimer
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingOutperform ➝ Outperform$53.00 ➝ $53.00+79.18%
10/24/2024UBS Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
D. Dai
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageBuy$50.00+69.49%
10/15/2024Cantor Fitzgerald
Subscribe to MarketBeat All Access for the recommendation accuracy rating
L. Watsek
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageOverweight
9/24/2024Royal Bank of Canada
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingOutperform ➝ Outperform$61.00 ➝ $61.00+80.85%
9/10/2024Stifel Nicolaus
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetBuy ➝ Buy$63.00 ➝ $68.00+86.56%
8/27/2024Citigroup
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetBuy ➝ Buy$60.00 ➝ $58.00+46.80%
8/8/2024JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetOverweight ➝ Overweight$69.00 ➝ $66.00+79.20%
7/29/2024Lifesci Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
C. Zhu
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeStrong-Buy
7/9/2024BTIG Research
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetBuy ➝ Buy$55.00 ➝ $62.00+57.00%
7/8/2024Mizuho
Subscribe to MarketBeat All Access for the recommendation accuracy rating
G. Suvannavejh
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageOutperform$50.00+45.94%
5/13/2024The Goldman Sachs Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetBuy ➝ Buy$53.00 ➝ $46.00+11.81%
2/22/2024Capital One Financial
Subscribe to MarketBeat All Access for the recommendation accuracy rating
T. Chiang
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOverweight
11/8/2023Guggenheim
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetBuy ➝ Buy$48.00 ➝ $44.00+42.53%
8/8/2023SVB Securities
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageOutperform$33.00+53.27%
3/23/2023Berenberg Bank
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageBuy$26.00+87.59%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Monday at 07:51 PM ET.


IDYA Forecast - Frequently Asked Questions

According to the research reports of 16 Wall Street equities research analysts, the average twelve-month stock price forecast for IDEAYA Biosciences is $53.67, with a high forecast of $68.00 and a low forecast of $27.00.

16 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for IDEAYA Biosciences in the last twelve months. There are currently 2 hold ratings, 13 buy ratings and 1 strong buy rating for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" IDYA shares.

According to analysts, IDEAYA Biosciences's stock has a predicted upside of 102.21% based on their 12-month stock forecasts.

Over the previous 90 days, IDEAYA Biosciences's stock had 2 downgrades by analysts.

IDEAYA Biosciences has been rated by research analysts at Cantor Fitzgerald, Citigroup, Leerink Partners, Leerink Partnrs, Oppenheimer, Royal Bank of Canada, Stephens, Stifel Nicolaus, UBS Group, and Wedbush in the past 90 days.

Analysts like IDEAYA Biosciences more than other "medical" companies. The consensus rating score for IDEAYA Biosciences is 2.94 while the average consensus rating score for "medical" companies is 2.80. Learn more on how IDYA compares to other companies.


This page (NASDAQ:IDYA) was last updated on 11/25/2024 by MarketBeat.com Staff
From Our Partners